Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.
Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer (LGSOC).
The phase 3 MILO/ENGOT trial (NCT01849874) examined binimetinib (Mektovi) vs physician’s choice of chemotherapy in patients with recurrent LGSOC. Binimetinib was utilized on the trial because it is a MEK inhibitor that targets alterations in the MAPK pathway, and most alterations seen in LGSOC are those that impact this pathway, according to Grisham. This makes LGSOC molecularly distinct from high-grade serous disease, where alterations such as p53, homologous recombination deficiency, and BRCA, are more common. The alterations that most frequently occur in LGSOC are KRAS, BRAF V600E, and NF1, Grisham concludes.